AKTX (Akari Therapeutics) Valuation Rank


AKTX Akari Therapeutics PLC AKTX
32 GF Score
Price $12.94
View Full Analysis

What is Akari Therapeutics Valuation Rank?

The Valuation Rank measures the current valuation of a business relative to other companies in the same industry and its own historical valuation. The companies are split in equal numbers and then ranked from 1 to 10, with 10 as the most undervalued and 1 as the most overvalued.

  1. Three factors:
    • Absolute valuation (medpsvalue) relative to current stock price, rank among all companies
    • Historical valuation over the past 10 years. Rank pe, ps, pocf, ev2ebit over their own historical values
    • Industry relative valuation
  2. Companies without enough data is not ranked
  3. Companies with negative earnings are ranked lower

These three factors are used to calculate the value score for every eligible company, with values from 1 to 10. The final ranked companies are split in equal numbers and ranked from 1 to 10, with 10 as the most undervalued, and 1 as the most overvalued. The numbers of companies in each rank are the same.

Akari Therapeutics Valuation Rank Related Terms

AKTX
32GF Score
Akari Therapeutics PLC AKTX
Valuation Rank is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Akari Therapeutics Business Description

Address 401 East Jackson Street, Suite 3300, Tampa, FL, USA, 33602
Akari Therapeutics PLC is an oncology company developing next-generation antibody-drug conjugates (ADCs) built around novel, proprietary payloads utilizing powerful biology to attack cancer. Its payload, PH1, targets RNA splicing by modulating the spliceosome, a complex machinery in the cell that converts pre-RNA into spliced RNA for translation into vital proteins for cell survival and growth. Its product pipeline is AKTX-101, which targets the Trop2 receptor on cancer cells and, with a proprietary linker, enables it to deliver its novel PH1 payload directly into the tumor with minimal off-target effects. and AKTX-102, an ADC candidate targeting CEACAM5 (Carcinoembryonic Antigen-related Cell Adhesion Molecule-5), a well-validated tumor antigen expressed across multiple solid tumors.
32GF Score

Get the complete analysis for AKTX

Valuation Rank is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$12.94
Price